

Heather A Wakelee

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7725269/heather-a-wakelee-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

146 papers	6,828 citations	38 h-index	81 g-index
162 ext. papers	9,081 ext. citations	6.2 avg, IF	5.65 L-index

#	Paper	IF	Citations
146	Bevacizumab's Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC.. <i>JTO Clinical and Research Reports</i> , 2022 , 3, 100274	1.4	0
145	In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?". <i>Journal of Thoracic Oncology</i> , 2022 , 17, e12-e14	8.9	
144	Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies. <i>Neuro-Oncology Advances</i> , 2021 , 3, v52-v62	0.9	0
143	Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.. <i>Cancer Treatment and Research Communications</i> , 2021 , 30, 100497	2	1
142	Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors. <i>JACC: CardioOncology</i> , 2021 , 3, 137-139	3.8	9
141	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. <i>Oncologist</i> , 2021 , 26, 523-532	5.7	1
140	Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. <i>Immunity</i> , 2021 , 54, 586-602.e8	32.3	16
139	Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response. <i>Cancer Discovery</i> , 2021 , 11, 1736-1753	24.4	14
138	Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. <i>Clinical Lung Cancer</i> , 2021 , 22, 201-209	4.9	8
137	Metabolomic profiling for second primary lung cancer: A pilot case-control study. <i>Lung Cancer</i> , 2021 , 155, 61-67	5.9	1
136	Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 868-872	8.9	15
135	Integrating Electronic Health Record, Cancer Registry, and Geospatial Data to Study Lung Cancer in Asian American, Native Hawaiian, and Pacific Islander Ethnic Groups. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1506-1516	4	2
134	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1030-1041	8.9	26
133	Tobacco Smoking and Risk of Second Primary Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 968-979	8.9	11
132	EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. <i>Clinical Lung Cancer</i> , 2021 ,	4.9	5
131	PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review. <i>Clinical Lung Cancer</i> , 2021 , 22, e329-e335	4.9	3
130	Two Cases of Pulmonary Tumor Thrombotic Microangiopathy Associated with ROS1-Rearranged Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021 , 22, e153-e156	4.9	3

129	Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021 , 22, e193-e200	4.9	2
128	Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 395-403	4.3	9
127	Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring. <i>Clinical Chemistry</i> , 2021 , 67, 534-542	5.5	2
126	Safety of lorlatinib following alectinib-induced pneumonitis in two patients with -rearranged non-small cell lung cancer: a case series. <i>Translational Lung Cancer Research</i> , 2021 , 10, 487-495	4.4	6
125	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With -Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100114	1.4	3
124	Radiological tumor classification across imaging modality and histology. <i>Nature Machine Intelligence</i> , 2021 , 3, 787-798	22.5	9
123	Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	7
122	Smoking Cessation After Lung Cancer Diagnosis and the Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab076	4.6	0
121	A Moving Target: Integration of Smoking Cessation Into Screening for Second Primary Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021 , 16, e59-e60	8.9	
120	Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 2029-2039	8.9	3
119	Incidence of Lung Cancer Among Never-Smoking Asian American, Native Hawaiian, and Pacific Islander Females. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	2
118	Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 1617-1625	13.4	20
117	Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report. <i>Clinical Lung Cancer</i> , 2021 , 22, e673-e677	4.9	0
116	Impact of Low-Dose Computed Tomography Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1479-1489	8.9	2
115	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1647-1662	8.9	48
114	Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of -Mutated Non-Small-Cell Lung Cancer.. <i>JCO Precision Oncology</i> , 2021 , 5, 153-162	3.6	0
113	TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. <i>Cancer Cell</i> , 2020 , 37, 742-745	24.3	38
112	A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS. <i>Cancer Treatment and Research Communications</i> , 2020 , 23, 100174	2	5

111	Adjuvant Chemotherapy. <i>Thoracic Surgery Clinics</i> , 2020 , 30, 179-185	3.1	0
110	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020 , 580, 245-251	50.4	147
109	U.S. Phase I First-in-human Study of Talrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 4785-4794	12.9	29
108	Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. <i>Nature Cancer</i> , 2020 , 1, 176-183	15.4	71
107	Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 274-281	12.9	49
106	Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. <i>Cancer Discovery</i> , 2020 , 10, 1826-1841	24.4	26
105	Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERA-VOLT Experience. <i>Cancer Cell</i> , 2020 , 38, 602-604	24.3	5
104	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020 , 183, 363-376.e13	56.2	76
103	Everolimus in the treatment of metastatic thymic epithelial tumors. <i>Lung Cancer</i> , 2020 , 149, 97-102	5.9	6
102	Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. <i>Oncotarget</i> , 2020 , 11, 18246-45	7.2	11
101	Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. <i>Lung Cancer</i> , 2019 , 137, 71-75	5.9	4
100	A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. <i>Oncology</i> , 2019 , 97, 102-111	3.6	38
99	Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. <i>Lung Cancer</i> , 2019 , 133, 144-150	5.9	49
98	Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. <i>Lung Cancer</i> , 2019 , 134, 42-45	5.9	19
97	Tumor Heterogeneity and Testing Discrepancy Confound ROS1 Detection in NSCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e111-e113	8.9	
96	First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2019 , 37, 946-953	2.2	196
95	Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes". <i>Lung Cancer</i> , 2019 , 137, 159-160	5.9	1
94	Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e21-e24	8.9	13

93	Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019 , 20, e208-e217	4.9	6
92	Osimertinib for -Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. <i>Oncologist</i> , 2019 , 24, 836-843	5.7	18
91	Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 767-778	8.9	16
90	Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. <i>Clinical Lung Cancer</i> , 2018 , 19, 377-386	4.9	
89	Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 165-183	8.9	52
88	Population-based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease. <i>Cancer Medicine</i> , 2018 , 7, 1211-1220	4.8	17
87	Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. <i>Clinical Cancer Research</i> , 2018 , 24, 2771-2779	12.9	86
86	Circulating tumor DNA testing in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018 , 119, 42-47	5.9	16
85	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1248-1268	8.9	331
84	A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 541-550	3.5	3
83	Incidence of lung cancer histologic cell-types according to neighborhood factors: A population based study in California. <i>PLoS ONE</i> , 2018 , 13, e0197146	3.7	5
82	Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. <i>Journal of Global Oncology</i> , 2018 , 4, 1-9	2.6	2
81	A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. <i>Journal of Thoracic Disease</i> , 2018 , 10, 219-227	2.6	4
80	Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an Tyrosine Kinase Inhibitor.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-13	3.6	2
79	Caution Needed for Analyzing the Risks of Second Cancers. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e1728-e173	4.9	14
78	Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018 , 19, e581-e588	4.9	14
77	ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 833-842	8.9	55
76	Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017 , 31, 31-44	3.1	6

75	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1183-1209	8.9	29
74	Lung cancer incidence trends in California by race/ethnicity, histology, sex, and neighborhood socioeconomic status: An analysis spanning 28 years. <i>Lung Cancer</i> , 2017 , 108, 140-149	5.9	15
73	A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2017 , 108, 173-182	5.9	8
72	Reply to Comment on Statin use and all-cancer survival: prospective results from the Women's Health Initiative. <i>British Journal of Cancer</i> , 2017 , 116, e2	8.7	1
71	Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017 , 18, 50-59	4.9	28
70	Risk Stratification for Second Primary Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2893-2899	2.2	50
69	Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017 , 125, 338-343	5.3	22
68	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. <i>Cancer Discovery</i> , 2017 , 7, 1394-1403	24.4	384
67	Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 16-21	4	11
66	Monitoring Neutropenia for Cancer Patients at the Point of Care. <i>Small Methods</i> , 2017 , 1, 1700193	12.8	3
65	Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS. <i>Current Treatment Options in Oncology</i> , 2017 , 18, 71	5.4	14
64	Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1610-1623	21.7	95
63	Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 129-136	8.9	43
62	A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS8576-TPS8576	2.2	2
61	The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC), and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (WTLC). <i>Journal of Clinical Oncology</i> , 2017 , 35, 241-241	2.2	
60	Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 2066-2081	8.9	40
59	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. <i>Nature Communications</i> , 2016 , 7, 11815	17.4	409
58	Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?. <i>Current Atherosclerosis Reports</i> , 2016 , 18, 72	6	11

57	Lung Cancer Survival Among Chinese Americans, 2000 to 2010. <i>Journal of Global Oncology</i> , 2016 , 2, 30-38.	6
56	Clinicopathologic Features of Advanced Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1411-82.	57
55	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. <i>Oncologist</i> , 2016 , 21, 762-70.	5.7 87
54	Statin use and all-cancer survival: prospective results from the Women's Health Initiative. <i>British Journal of Cancer</i> , 2016 , 115, 129-35.	8.7 64
53	Differences in Active and Passive Smoking Exposures and Lung Cancer Incidence Between Veterans and Non-Veterans in the Women's Health Initiative. <i>Gerontologist, The</i> , 2016 , 56 Suppl 1, S102-11.	5 14
52	Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial. <i>Clinical Lung Cancer</i> , 2016 , 17, 10-7.e1.	4.9 25
51	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 613-638.	8.9 164
50	Integrated digital error suppression for improved detection of circulating tumor DNA. <i>Nature Biotechnology</i> , 2016 , 34, 547-555.	44.5 589
49	Survival among Never-Smokers with Lung Cancer in the Cancer Care Outcomes Research and Surveillance Study. <i>Annals of the American Thoracic Society</i> , 2016 , 13, 58-66.	4.7 17
48	Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 989-93.	4 17
47	Lung Cancer in Never Smokers. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 893, 43-57.	3.6 76
46	Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health Initiative. <i>Journal of Clinical Oncology</i> , 2016 , 34, 360-8.	2.2 24
45	A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3019-3019.	2.2 22
44	Pretreatment biopsy for thymic epithelial tumors-does histology subtype matter for treatment strategy?. <i>Journal of Thoracic Disease</i> , 2016 , 8, 1895-900.	2.6 1
43	Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. <i>Journal of Cutaneous Pathology</i> , 2016 , 43, 339-46.	1.7 69
42	Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy. <i>Clinical Therapeutics</i> , 2016 , 38, 1567-76.	3.5 7
41	Molecular profiling of single circulating tumor cells from lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E8379-E8386.	11.5 79
40	The Burden of Cancer in Asian Americans: A Report of National Mortality Trends by Asian Ethnicity. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1371-1382.	4 55

39	Physical activity and sedentary behavior in relation to lung cancer incidence and mortality in older women: The Women's Health Initiative. <i>International Journal of Cancer</i> , 2016 , 139, 2178-92	7.5	20
38	ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. <i>Cancer Epidemiology</i> , 2015 , 39, 307-12	2.8	16
37	Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy. <i>American Journal of Ophthalmology</i> , 2015 , 160, 799-805.e1	4.9	43
36	Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. <i>Lung Cancer</i> , 2015 , 89, 280-6	5.9	13
35	Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. <i>Lung Cancer</i> , 2015 , 90, 1-7	5.9	10
34	Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015 , 16, 366-73	4.9	19
33	Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. <i>Lung Cancer</i> , 2015 , 87, 34-8	5.9	23
32	Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1004-13	8.9	33
31	Novel Treatments for Thymoma and Thymic Carcinoma. <i>Frontiers in Oncology</i> , 2015 , 5, 267	5.3	1
30	Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1745-53	8.9	74
29	GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray. <i>Anticancer Research</i> , 2015 , 35, 669-76	2.3	5
28	Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy. <i>Seminars in Oncology</i> , 2014 , 41, 40-56	5.5	40
27	Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. <i>Clinical Lung Cancer</i> , 2014 , 15, 202-6	4.9	55
26	Review of the current targeted therapies for non-small-cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2014 , 5, 576-87	2.5	50
25	Anti-Angiogenic Agents in Metastatic NSCLC 2014 , 527-540		
24	An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. <i>Nature Medicine</i> , 2014 , 20, 548-54	50.5	1363
23	miR-1 induces growth arrest and apoptosis in malignant mesothelioma. <i>Chest</i> , 2013 , 144, 1632-1643	5.3	39
22	Response. <i>Chest</i> , 2013 , 144, 1971-1972	5.3	

21	Management of early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2013 , 2, 315	4.4	1
20	Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2013 , 2, 403-10	4.4	23
19	Smoking and estrogen plus progestin (E+P) and lung cancer incidence and mortality.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1524-1524	2.2	
18	A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 815-24	3.5	5
17	The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 563-71	3.5	14
16	Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, 231-7	4	59
15	Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2012 , 13, 52-58	4.9	72
14	A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1574-82	8.9	43
13	Survival following non-small cell lung cancer among Asian/Pacific Islander, Latina, and Non-Hispanic white women who have never smoked. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 545-54	4	24
12	Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. <i>Clinical Lung Cancer</i> , 2009 , 10, 395-404	4.9	2
11	Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2008 , 9, 9-15	4.9	3
10	Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2008 , 9, 346-51	4.9	18
9	Adjuvant chemotherapy for resected non-small cell lung cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2008 , 20, 198-203	1.7	10
8	Antibodies to vascular endothelial growth factor in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2008 , 3, S113-8	8.9	12
7	Lung cancer incidence in never smokers. <i>Journal of Clinical Oncology</i> , 2007 , 25, 472-8	2.2	388
6	Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. <i>Cancer</i> , 2006 , 106, 2208-17	6.4	51
5	Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 441-6	8.9	34
4	Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors. <i>Clinical Lung Cancer</i> , 2005 , 7 Suppl 1, S6-12	4.9	6

3	Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. <i>Clinical Lung Cancer</i> , 2005 , 7 Suppl 1, S31-8	4.9	20
2	Docetaxel in advanced non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2005 , 5, 13-24	3.5	7
1	Novel approaches for the treatment of small cell lung cancer. <i>Hematology/Oncology Clinics of North America</i> , 2004 , 18, 499-518	3.1	5